Immunomedics, Inc. Securities Litigation (2018)

If you purchased a significant amount of shares of Immunomedics, Inc. (NASDAQ: IMMU), you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:Immunomedics, Inc.
Date Filed:December 27th, 2018
Sector:Health Care
Industry:Biotechnology: In Vitro & In Vivo Diagnostic Substances
Class Start Date:February 8th, 2018
Class End Date:January 18th, 2019

According to the Complaint, Immunomedics purports to be a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.

The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Immunomedics, Inc.

First Identified Complaint

Ahmad Odeh, et al. v. Immunomedics, Inc., et al.

Date Filed:December 27th, 2018
Class Period Start:August 23rd, 2018
Class Period End:December 20th, 2018
First Identified Complaint Filings
#Document TitleFiling Date